|Bid||0.00 x 900|
|Ask||0.00 x 2200|
|Day's Range||17.02 - 18.16|
|52 Week Range||12.77 - 32.99|
|Beta (3Y Monthly)||3.87|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ACADIA Pharmaceuticals Inc’s (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Read More...
Acadia (ACAD) delivered earnings and revenue surprises of 13.79% and 0.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of 50 cents per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a ...
Exelixis (EXEL) reported net income of $126.6 million in the third quarter compared to $81.4 million in the third quarter of 2017. The company’s net income over the first nine months of this year amounted to $330.0 million compared to $115.7 million in the same period the prior year.
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Oct. 29) Gamida Cell Ltd (NASDAQ: GMDA ) NeoGenomics, Inc. (NASDAQ: ...
The SPDR Biotech ETF ( XBI) had been up 18% for 2018 at the start of September. Since then the Biotech ETF has given up nearly all of its gains and is now up less than 1% on the year. But not all biotechs have been poor performers during this time, and some may be poised to gain 15% or more in the final few weeks of 2018. The stock reached an intraday high of $23.50 on October 18, and should the stock be able to rise above technical resistance at $24, it could be on its way to $27.20. Should the stock rise above technical resistance at $45.25, the shares could increase to roughly $50.
How Is Acadia Pharmaceuticals Positioned Now? Acadia Pharmaceuticals’ (ACAD) Nuplazid generated revenues of $57.1 million in the second quarter of 2018 compared to $30.5 million in the second quarter of 2017, reflecting an ~87% YoY (year-over-year) growth. After the second quarter of 2018, Acadia Pharmaceuticals lowered its sales revenue guidance for Nuplazid to $210 million–$255 million for fiscal 2018.
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will generate revenues of $56.07 million in the third quarter of 2018, representing a ~57.59% YoY (year-over-year) growth. Its net revenues grew ~87% to $57.06 million in the second quarter, from $30.5 million in the second quarter of 2017.
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will report net income of -$63.01 million for the third quarter of 2018. It was -$63.3 million in the second quarter, which compares to -$67.4 million in the second quarter of 2017. In the first half of this year, its net income was -$117.66 million. In the first half of 2017, it was -$155.3 million.
The FDA issued a positive statement on the company's drug for Parkinson's disease psychosis, but investors still need to watch one important metric.
There has been no shortage of encouraging news over the past few months across the biotech sector, but the patterns that are appearing on several key charts are suggesting that the story could be in the early stages of shifting. Active traders who are looking for exposure to biotechnology often turn to exchange-traded products such as the SPDR S&P Biotech ETF. As you can see from the chart below, the price has been trading along a well-defined trendline over the past couple of years, but the recent close below the trendline suggests that the ETF is in the early stages of a downtrend.
Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018, which reflected ~6% year-over-year (or YoY) growth. Portola Pharmaceuticals’ net revenues grew from $8.92 million in the first half of 2018 to $10.66 million in the first half of 2017, reflecting ~20% YoY growth.
In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).
Technical analysis suggests that Acadia Pharmaceuticals Inc. ( ACAD), BeiGene Ltd. ( BGNE) and Intercept Pharmaceuticals Inc. ( ICPT) are three such stocks that could see the significant gains. Acadia shares have skyrocketed higher over the past few weeks and are trading around a technical resistance level at $21.50. Should the stock be able to rise above that level of resistance, the shares could rally by 13% to a price of $24, from its current price of around $21.40.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) with a market-capitalization of US$2.48b, rarely draw their attention. Despite this, commonly overlooked Read More...